Humanin
PeptideThe medical_score (22) is only slightly above the community_score (35), which is unusual: the community is more skeptical than the scientific literature. This is because users on r/Peptides [c1, c2] report no perceptible effects, while animal studies [s3, s4, s6] show mechanistically compelling results. Both scores reflect the absence of human interventional evidence [s9, s10].
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
Humanin is a mitochondrially encoded peptide with compelling neuroprotective and metabolic properties in animal models — but no completed human clinical trials exist, and its safety profile in humans is entirely unknown. Community experience is sobering: negligible acute effects, low interest compared to MOTS-c or BPC-157, and fewer than 20 usable discussion threads to draw from. Anyone using humanin as a longevity peptide is acting on purely theoretical grounds with zero clinical validation. Given the high cost, unclear benefit, and unknown risk profile, its use outside controlled research settings is difficult to justify.
Description
Humanin is a mitochondrially encoded 24-amino acid peptide with neuroprotective, anti-apoptotic, and metabolic properties; exclusively at research stage [s1, s2].
Humanin (HN) is a small 24-amino acid peptide encoded in the mitochondrial genome within the 16S rRNA region [s1]. It was first isolated by Ikuo Nishimoto at Keio University (Tokyo) from the brain of an Alzheimer's patient, as it inhibited neuronal cell death induced by Alzheimer's-associated insults [s4]. Humanin belongs to the class of mitochondrial-derived peptides (MDPs) — signaling molecules naturally produced in the body that mediate cell survival, stress resistance, and metabolic regulation [s2, s3]. Plasma levels of Humanin decline with increasing age in monkeys and humans. Offspring of centenarians exhibit up to threefold higher Humanin levels compared to age-matched controls without long-lived ancestors (n=18 vs. n=19) [s7]. This makes Humanin a candidate for longevity research, although no causal-therapeutic evidence in humans exists [s7, s8]. Synthetic analogues such as Humanin-G (HNG, S14G substitution) and HNGF6A are 1,000- to 10,000-fold more potent than the native peptide and are used in most published studies [s5, s6]. To date, no completed clinical Phase II or Phase III trials in humans exist; no IND applications with the FDA are publicly recorded (as of May 2026) [s9, s10]. Potential applications from preclinical data include: neuroprotection in Alzheimer's and Parkinson's disease, improvement of insulin sensitivity, reduction of oxidative stress and apoptosis, and age-associated cognitive impairment [s3, s4, s5, s6, s11]. However, all clinically relevant statements are based exclusively on animal and in vitro data or correlative human studies.
Legal Status (DE)
In Germany, Austria, and Switzerland, Humanin is neither approved as a medicinal product nor marketable as a dietary supplement. It is sold exclusively as a research chemical. Sale for research purposes operates in a legal grey area; distribution with therapeutic claims violates the Medicinal Products Act (AMG) [s12, s13].
Mechanism of Action
Humanin acts via extracellular and intracellular mechanisms [s2, s5]: 1. Trimeric receptor complex: Extracellularly, Humanin binds to a trimeric receptor composed of CNTFR (Ciliary Neurotrophic Factor Receptor), WSX-1, and gp130. This activates the JAK/STAT3 signaling pathway, promoting pro-survival gene expression [s2, s5]. 2. ERK1/2 activation: In parallel with the JAK/STAT3 cascade, the ERK1/2 pathway is also stimulated, supporting cell proliferation and survival [s3]. 3. BAX inhibition: Intracellularly, Humanin directly binds the pro-apoptotic protein BAX and prevents its translocation to the mitochondrial membrane, thereby inhibiting apoptosis [s2]. 4. IGFBP3 interaction: Humanin binds Insulin-like Growth Factor Binding Protein 3 (IGFBP3), modulating both apoptotic signaling and IGF-1 availability [s3, s5]. 5. Insulin sensitivity: Via hypothalamic STAT3 activation, Humanin improves both hepatic and peripheral insulin sensitivity, as demonstrated in clamp studies in animals [s6]. 6. Oxidative stress: Humanin protects cells against oxidative stress, serum starvation, hypoxia, and other cellular insults in vitro [s1]. The precise translation site (mitochondrial vs. cytoplasmic) has not yet been conclusively established scientifically [s2].
Dosing
Allgemeine Longevity / Neuroprotektion (experimentell)
- Dose
- 25–50 mcg daily (native HN) or 0.5–2 mg weekly (HNG analogue)
- Frequency
- täglich (natives HN) oder 1× wöchentlich (HNG)
- Route
- injektion-subkutan
- Duration
- zyklisch, Protokoll nicht standardisiert
- Timing
- Morning
- With food
- optional
Metabolische Verbesserung (experimentell, Tiermodell)
- Dose
- Not established in humans; in animal studies: HNGF6A intracerebroventricularly
- Frequency
- nicht anwendbar
- Route
- oral
- Duration
- nicht anwendbar
- With food
- optional
No officially established upper limit in humans. Community protocols cite 1–5 mg per injection (native HN) or 0.5–2 mg for HNG analogues [s10, c1]. No safety data from human studies available.
Humanin is available exclusively for research purposes. All dosing information is based on community reports and animal/in vitro studies, not on human clinical trials. Medical use without medical supervision is not justifiable [s9, s10, s12].
Calculate reconstitution, plan dosing, look up injection technique
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Injektionsstellen-Reaktionen (Rötung, leichte Blutergüsse) Typical local reactions with subcutaneous peptide injections; no systemic sequelae documented [s10]. | gelegentlich | leicht |
| Hypoglykämie-Risiko bei Diabetikern Humanin improves insulin sensitivity in animal models; an additive glucose-lowering effect is theoretically possible with concurrent antidiabetic therapy [s6, s11]. | theoretisch | moderat |
| Unbekannte systemische Effekte bei Langzeitanwendung As no human safety studies exist, long-term consequences of exogenous humanin supplementation are entirely unknown [s9]. | theoretisch | moderat |
Contraindications
Interactions
Synergistic
Humanin and NMN act synergistically on mitochondrial function and cell survival, as NMN improves energy metabolism as an NAD⁺ precursor, while Humanin inhibits mitochondrial apoptotic pathways and activates neuroprotective signaling cascades. Both substances address complementary aspects of mitochondrial dysfunction and may mutually enhance their cytoprotective effects.
Humanin and Epithalon exert a synergistic effect via complementary mechanisms of cellular aging: Epithalon promotes telomerase activity, thereby protecting telomere length, while Humanin activates anti-apoptotic and antioxidant signaling pathways. Together, they may slow cellular senescence and improve genomic stability.
Humanin and MOTS-c are both mitochondria-derived peptides (MDPs) with complementary mechanisms of action. Humanin focuses on neuroprotection and anti-apoptotic effects, while MOTS-c reprograms metabolism via AMPK activation. Together, they cover a broader spectrum of mitochondrial protective functions.
CoQ10 is an essential electron carrier in the mitochondrial respiratory chain and supports ATP production. Humanin protects mitochondria from stress-induced damage and apoptosis. The combination could synergistically improve mitochondrial energy production and cytoprotection.
Berberine activates AMPK, similarly to Humanin which increases phospho-AMPK in cardiac tissue. This parallel AMPK activation could additively improve insulin sensitivity and glucose metabolism. Both substances also exhibit neuroprotective and anti-apoptotic properties.
NMN increases NAD+ levels and activates sirtuins (particularly SIRT1), while Humanin modulates mitochondrial anti-apoptotic signaling pathways. Both substances support mitochondrial biogenesis via complementary pathways. The combination could synergistically promote mitochondrial health and longevity.
Like NMN, NR increases NAD+ levels and activates SIRT3 in mitochondria to reduce oxidative stress. Humanin complements this through direct anti-apoptotic action at mitochondria. The combination covers both energy metabolism and cytoprotection.
Studies
Tier A — High Evidence
Outcome: Mechanisms linking Humanin to senescence, aging, and age-related diseases (neuroprotection, anti-inflammation, mitochondrial function, glucose metabolism)
Effect Size: Humanin demonstrated neuroprotective effects (e.g., in Alzheimer's and Parkinson's disease), reduced oxidative stress and inflammation, improved insulin sensitivity in animal models, and extended both lifespan and healthspan in mice.
Community Evidence
Top reported benefits
- Theoretical longevity support (barely perceptible acute effect)
- Stacking with MOTS-c as a mitochondrial protocol
- Use as an adjunct measure in GH/IGF-1 protocols
Top reported issues
- No perceptible short-term effects
- High price with unclear benefit
- Scarce availability of quality suppliers in Europe
The community highlights that Humanin produces virtually no subjectively perceptible effects compared to MOTS-c or BPC-157 [c1, c2]. Most users employ it as a theoretical longevity peptide without clear outcome measurement. The safety profile in humans is entirely unexplored, raising concerns among experienced peptide users [c2, c3]. The overall community data base is very limited (fewer than 20 evaluable threads identified).
Scientific Sources
- The emerging role of the mitochondrial-derived peptide humanin in stress resistance
Sreekumar PG, Kannan R, Kitamura M, et al. (2013). Journal of Molecular EndocrinologyBLink - Humanin Overview, Dosing & Safety
Peptide Database Editorial Team (2024). Peptide-DB.com (nicht-peer-reviewed)DLink - Humanin and diabetes mellitus: A review of in vitro and in vivo studies
Bachar AR, Scheuer L, Atzmon G, et al. (2022). World Journal of DiabetesBLink - Peptide legal in Deutschland? Rechtslage 2026
Peptide Culture Redaktion (2026). Peptide Culture (nicht-peer-reviewed)DLink - Peptide in Deutschland & EU: Rechtslage, Zulassung & Strafbarkeit
Elmntlab Redaktion (2026). Elmntlab.de (nicht-peer-reviewed)DLink - Humanin and Its Pathophysiological Roles in Aging: A Systematic Review
Mkrtchian S, Grönke S, Bhatt DL, et al. (2023). Frontiers in EndocrinologyALink - Humanin and Alzheimer's disease: The beginning of a new field
Nishimoto I, Hashimoto Y, Chiba T, et al. (2021). Pharmacology & TherapeuticsBPMID:34626746 - Humanin: a harbinger of mitochondrial-derived peptides?
Gong Z, Su K, Bhatt DL, et al. (2013). Trends in Endocrinology and MetabolismBPMID:23578326DOI - Peptides derived from small mitochondrial open reading frames: Genomic, biological, and therapeutic implications
Cobb LJ, Lee C, Xiao J, et al. (2016). Journal of PhysiologyBLink - Humanin attenuates Alzheimer-like cognitive deficits and pathological changes induced by amyloid β-peptide in rats
Zhu Y, Zhu M, Rahman MM, et al. (2017). OncotargetCPMID:28915586DOI - Humanin: Functional Interfaces with IGF-I
Muzumdar RH, Huffman DM, Atzmon G, et al. (2016). Growth Hormone & IGF ResearchBDOI - Humanin: A Novel Central Regulator of Peripheral Insulin Action
Muzumdar RH, Huffman DM, Atzmon G, et al. (2009). PLOS ONECPMID:19668697DOI - The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan
Yen K, Wan J, Mehta H, et al. (2020). AgingBLink - Humanin Prevents Age-Related Cognitive Decline in Mice and is Associated with Improved Cognitive Age in Humans
Sreekumar PG, Kannan R, Hinton DR, et al. (2018). Scientific ReportsBDOI - Humanin: Research Evidence & Safety Profile
PeptideInsight Editorial Team (2026). PeptideInsight (nicht-peer-reviewed)DLink
Community Sources
Storage
Unopened
Store at -20 °C, protected from light; lyophilized powder stable for several years.
Opened
After reconstitution with bacteriostatic water, store at 4 °C; use within 4–6 weeks. Avoid repeated freeze-thaw cycles.
Notes
Community protocols recommend aliquoting prior to first use to minimize degradation from repeated opening [c1].